AKU's Q4 Revenue Up 168%, CPRX Expects 2022 Revenue To Grow 38%-45%, VIRX Awaits NAVAL-1 Trial Data

SQZ Biotechnologies Co. (SQZ) expects to present clinical data from COMMANDER-001, a phase I/II clinical trial of SQZ-eAPC-HPV for the treatment of HPV16+ advanced or metastatic solid tumors, in the second half of this year.

from RTT - Earnings https://ift.tt/kmhAzxv
via IFTTT